Wintermute Biomedical are excited our ZosterEase Phase Ib clinical trial’s patient recruitment is now fulfilled.
Preliminary safety results expected shortly. Read more here.
Preliminary safety results expected shortly. Read more here.
Company CEO Dr. Tom Rau to present on high potential topical treatment for Shingles
Wintermute Biomedical is set to make a significant impact at the upcoming BioBoston International Convention, where CEO Dr. Tom Rau will present the company's revolutionary topical technology for treating shingles. This breakthrough comes after 12 years of intensive research and development, promising a game-changing solution for the 1 in 3 individuals affected with shingles globally.
What sets Wintermute's Solexan™ apart is it's versatility and practicality as a patented, first-in-class topical antiviral foam patients can self-apply that directly targets the shingles virus (VZV).
The presentation will highlight recent promising preclinical results from its ZosterEase human Phase Ib clinical trial, further underscoring the potential of this technology to treat shingles infection and pain.
Want to know more whilst at BioBoston? Book a time with Dr Tom Rau through Bio Partnering now.
Details of the talk:
Location: Bio Boston International Convention.
When: Tuesday, June 17 at 4:30pm in Room 153A
Title: Novel ammonium carboxylate salt as high potential treatment option for Shingles.